What is the specific type and stage (I, II, III, IV) of my melanoma? What does the Breslow depth, ulceration status,...
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Question asked:
What is the specific type and stage (I, II, III, IV) of my melanoma? What does the Breslow depth, ulceration status, and sentinel node biopsy result (if applicable) mean for my prognosis and risk of recurrence?
Understanding Your Melanoma Type, Stage, and Prognosis
I'd like to help you understand your melanoma's specifics, but I notice you haven't shared your pathology report or [ID removed] yet. To give you accurate, personalized educational information about your type, stage, and what your test results mean, I'll need you to upload:
- Your pathology report (from your skin biopsy)
- Your surgical pathology report (if you've had surgery)
- Your sentinel lymph node biopsy (SLNB) results (if applicable)
- Any imaging reports (CT, PET, or MRI scans)
Once you share these documents, I can help you understand what they mean in plain language. In the meantime, let me explain what these key findings generally mean so you'll be prepared:
Understanding Key Melanoma Measurements
Breslow Depth
According to the NCCN Guidelines for Patients: Melanoma, Breslow thickness is "a measure of how deep the melanoma tumor has grown into the skin." Think of your skin as having layers—the Breslow depth tells doctors how far down into those layers the cancer cells have spread.
Why this matters: Deeper melanomas generally have a higher risk of spreading to lymph nodes or other parts of the body. This measurement directly influences:
- Whether you need additional testing (like sentinel lymph node biopsy)
- Your stage classification
- What treatments your doctor might recommend
Ulceration Status
Ulceration means there's a break or open sore in the skin where the melanoma is located. According to NCCN Guidelines, ulceration is an important prognostic factor—meaning it helps predict how the cancer might behave.
What this means:
- Ulcerated melanoma = the cancer has broken through the skin surface
- Non-ulcerated melanoma = the skin surface is still intact
Ulcerated melanomas tend to be more aggressive and carry a higher risk of recurrence compared to non-ulcerated melanomas at the same depth.
Sentinel Lymph Node Biopsy (SLNB)
According to NCCN Guidelines, a sentinel lymph node biopsy is "surgery to find and remove a sentinel lymph node to see if it contains cancer cells."
How it works:
- Doctors use dyes and radioactive tracers to identify the first lymph node(s) that drain fluid from where your melanoma was
- They remove and examine these "sentinel" nodes under a microscope
- This tells them if cancer cells have started spreading to your lymph system
What the results mean:
- Negative (no cancer cells): Lower risk of spread; typically stage I or II
- Positive (cancer cells found): Cancer has begun spreading to lymph nodes; typically stage III
Melanoma Stages Explained
According to the NCCN Guidelines for Patients: Melanoma, there are five stages:
| Stage | What It Means | Key Features | |-----------|------------------|-----------------| | Stage 0 (In Situ) | Cancer is only in the top skin layer | Hasn't invaded deeper layers | | Stage I | Melanoma is localized to the skin | Thin to intermediate depth; no lymph node involvement | | Stage II | Melanoma is in the skin but thicker or ulcerated | Higher risk features but no lymph node spread | | Stage III | Cancer has spread to regional lymph nodes or nearby skin | Found in lymph nodes or satellite/in-transit tumors | | Stage IV (Metastatic) | Cancer has spread to distant organs or distant lymph nodes | Spread beyond the original area |
What These Findings Mean for Recurrence Risk
According to NCCN Guidelines, your risk of recurrence depends on several factors working together:
Higher Risk Factors:
- Deeper Breslow depth (thicker tumors)
- Ulceration present
- Positive sentinel lymph node biopsy
- Higher mitotic rate (more cancer cells actively dividing)
Lower Risk Factors:
- Shallow Breslow depth (thinner tumors)
- No ulceration
- Negative sentinel lymph node biopsy
- Lower mitotic rate
What You Should Do Next
**Please upload your [ID removed] so I can:
- ✅ Identify your specific stage
- ✅ Explain what YOUR Breslow depth means
- ✅ Clarify YOUR ulceration status
- ✅ Interpret YOUR sentinel node results
- ✅ Help you understand YOUR specific recurrence risk
Questions to Ask Your Oncologist
Once you know your stage and test results, these questions will help you understand your situation better:
-
"What is my exact stage, and what does that mean for my treatment options?"
-
"What is my Breslow depth, and how does that affect my prognosis?"
-
"Do I have ulceration, and how does that change my risk of recurrence?"
-
"What were my sentinel lymph node biopsy results, and what do they tell us about whether the cancer has spread?"
-
"Based on all my test results together, what is my estimated risk of recurrence, and what can we do to reduce that risk?"
-
"What follow-up care and surveillance will I need, and how often?"
Key Takeaway
According to the NCCN Guidelines for Patients: Melanoma, "The good news is that most melanomas are found in earlier stages. And even if melanoma is diagnosed at a later stage, many effective treatments are available."
Please share your pathology and surgical reports, and I'll provide specific, detailed explanations of what YOUR results mean.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Source Guidelines
NCCN Guidelines for Patients: Melanoma (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with diagnosis for Melanoma patients
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: